| scholarly article | Q13442814 |
| P50 | author | Karin E. Bornfeldt | Q87887672 |
| P2860 | cites work | Chronic Inflammatory Disorders and Risk of Type 2 Diabetes Mellitus, Coronary Heart Disease, and Stroke | Q57388112 |
| Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice | Q59284858 | ||
| Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis | Q61514318 | ||
| Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes | Q62583515 | ||
| COMBINED CLINICAL AND PATHOLOGIC STUDY OF DIABETIC AND NONDIABETIC PERIPHERAL ARTERIAL DISEASE | Q76961606 | ||
| Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts | Q83393056 | ||
| Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) | Q85063666 | ||
| Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human | Q21562369 | ||
| Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 | ||
| The response-to-retention hypothesis of early atherogenesis | Q24629974 | ||
| Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses | Q24631052 | ||
| Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis | Q24634165 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Insulin resistance, hyperglycemia, and atherosclerosis | Q27011696 | ||
| S100A8 and S100A9 in cardiovascular biology and disease | Q27024450 | ||
| Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association | Q28235865 | ||
| Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events | Q28238975 | ||
| Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes | Q28299458 | ||
| Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia | Q28565000 | ||
| Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin | Q28574224 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Loss-of-function mutations in APOC3, triglycerides, and coronary disease | Q30408720 | ||
| Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis | Q30412997 | ||
| Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation | Q30431948 | ||
| High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. | Q33565025 | ||
| Testing the role of myeloid cell glucose flux in inflammation and atherosclerosis | Q33612986 | ||
| Succinate is an inflammatory signal that induces IL-1β through HIF-1α. | Q33652731 | ||
| Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity | Q33724394 | ||
| The p75 neurotrophin receptor is required for the major loss of sympathetic nerves from islets under autoimmune attack | Q33789390 | ||
| Mouse Models for Type 1 Diabetes | Q33794336 | ||
| Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis | Q34021724 | ||
| Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association | Q34219439 | ||
| Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages | Q34316035 | ||
| miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. | Q34324735 | ||
| High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide | Q34334697 | ||
| Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. | Q34336208 | ||
| Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice | Q34399952 | ||
| Loss-of-function mutations in APOC3 and risk of ischemic vascular disease | Q34425444 | ||
| Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study | Q34433105 | ||
| Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study | Q34440576 | ||
| Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice | Q34485920 | ||
| Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes | Q34693197 | ||
| Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice. | Q34734402 | ||
| Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy | Q34742779 | ||
| The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. | Q34801576 | ||
| Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice | Q35043471 | ||
| Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis | Q35114963 | ||
| Triglycerides and heart disease: still a hypothesis? | Q35120360 | ||
| Fractalkine is a novel human adipochemokine associated with type 2 diabetes | Q35796996 | ||
| Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. | Q35849515 | ||
| Morphological characteristics of coronary atherosclerosis in diabetes mellitus | Q36405152 | ||
| HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. | Q36603504 | ||
| Type 1 diabetes and coronary artery disease | Q36634829 | ||
| Acyl-CoA synthetase 1 is induced by Gram-negative bacteria and lipopolysaccharide and is required for phospholipid turnover in stimulated macrophages | Q36742281 | ||
| Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes | Q36842628 | ||
| The macrophage at the crossroads of insulin resistance and atherosclerosis | Q36843648 | ||
| Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. | Q36883079 | ||
| All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database | Q37022658 | ||
| Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? | Q37026106 | ||
| The expression of inflammatory genes is upregulated in peripheral blood of patients with type 1 diabetes | Q37106490 | ||
| Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis | Q37201521 | ||
| Increased atherosclerosis in streptozotocin-induced diabetic mice | Q37353969 | ||
| PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice | Q37397476 | ||
| Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals | Q37400830 | ||
| Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study | Q37403220 | ||
| Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells | Q37405753 | ||
| The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease | Q37412673 | ||
| Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition | Q37459831 | ||
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Toll-like receptor agonists promote prolonged triglyceride storage in macrophages. | Q37536615 | ||
| Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. | Q37635856 | ||
| 2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis | Q37666671 | ||
| Cooperation between brain and islet in glucose homeostasis and diabetes | Q37698362 | ||
| Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis | Q37711215 | ||
| Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. | Q38059912 | ||
| Metabolism of inflammation limited by AMPK and pseudo-starvation | Q38074586 | ||
| Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes | Q38218644 | ||
| Macrophages, immunity, and metabolic disease | Q38230879 | ||
| The cardiovascular effects of metformin: lost in translation? | Q38254257 | ||
| Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial | Q38441000 | ||
| Immunometabolism: an emerging frontier | Q38876919 | ||
| Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. | Q38976590 | ||
| Cooperation of adenosine with macrophage Toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene. | Q39564669 | ||
| Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators | Q41082185 | ||
| Diabetes and cardiovascular disease. The Framingham study | Q41509493 | ||
| Methotrexate--how does it really work? | Q43144564 | ||
| Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial | Q43624795 | ||
| Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study | Q44440008 | ||
| Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus | Q44759159 | ||
| Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice | Q45120387 | ||
| Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. | Q45161321 | ||
| Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state | Q45417284 | ||
| Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. | Q45739869 | ||
| Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation | Q46513450 | ||
| Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia | Q46537808 | ||
| Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice | Q46618830 | ||
| Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles | Q46805800 | ||
| Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes | Q47441517 | ||
| Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. | Q51353698 | ||
| Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. | Q51376929 | ||
| Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. | Q53648299 | ||
| Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. | Q54198243 | ||
| Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. | Q54610885 | ||
| NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis | Q56991358 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2689-2697 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture | |
| P478 | volume | 64 |
| Q57134943 | Activated protein C reverses epigenetically sustained p66 expression in plaque-associated macrophages in diabetes |
| Q37083092 | Does Elevated Glucose Promote Atherosclerosis? Pros and Cons |
| Q36562533 | Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes |
| Q47881764 | Regulation of Macrophage Apoptosis and Atherosclerosis by Lipid-Induced PKCδ Isoform Activation |
| Q50205101 | The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype |
Search more.